PDGFRA and facioscapulohumeral muscular dystrophy: Our results demonstrate for the first time that FSHD patients’ muscles are characterised by an increased number of both CD201+ and PDGFRA+ non-myogenic mesenchymal cells, and that this change is prominent in muscles displaying signs of early damage.